Identification and functional characterization of a novel mutation in the NKX2-1 gene: comparison with the data in the literature.

Authors: Nettore, Immacolata Cristina  Mirra, Paola  Ferrara, Alfonso Massimiliano  Sibilio, Annarita  Pagliara, Valentina  Kay, Claudia Suemi Kamoi  Lorenzoni, Paulo Josè  Werneck, Lineu Cesar  Bruck, Isac  Dos Santos, Lucia Helena Coutinho  Beguinot, Francesco  Salvatore, Domenico  Ungaro, Paola  Fenzi, Gianfranco  Scola, Rosana Herminia  Macchia, Paolo Emidio 
Citation: Nettore IC, etal., Thyroid. 2013 Jun;23(6):675-82. doi: 10.1089/thy.2012.0267.
Pubmed: (View Article at PubMed) PMID:23379327
DOI: Full-text: DOI:10.1089/thy.2012.0267


BACKGROUND: NKX2-1 mutations have been described in several patients with primary congenital hypothyroidism, respiratory distress, and benign hereditary chorea, which are classical manifestations of the brain-thyroid-lung syndrome (BTLS).
METHODS: The NKX2-1 gene was sequenced in the members of a Brazilian family with clinical features of BTLS, and a novel monoallelic mutation was identified in the affected patients. We introduced the mutation in an expression vector for the functional characterization by transfection experiments using both thyroidal and lung-specific promoters.
RESULTS: The mutation is a deletion of a cytosine at position 834 (ref. sequence NM_003317) (c.493delC) that causes a frameshift with formation of an abnormal protein from amino acid 165 and a premature stop at position 196. The last amino acid of the nuclear localization signal, the whole homeodomain, and the carboxy-terminus of NKX2-1 are all missing in the mutant protein, which has a premature stop codon at position 196 (p.Arg165Glyfs*32). The p.Arg165Glyfs*32 mutant does not bind DNA, and it is unable to transactivate the thyroglobulin (Tg) and the surfactant protein-C (SP-C) promoters. Interestingly, a dose-dependent dominant negative effect of the p.Arg165Glyfs*32 was demonstrated only on the Tg promoter, but not on the SP-C promoter. This effect was also noticed when the mutation was tested in presence of PAX8 or cofactors that synergize with NKX2-1 (P300 and TAZ). The functional effect was also compared with the data present in the literature and demonstrated that, so far, it is very difficult to establish a specific correlation among NKX2-1 mutations, their functional consequence, and the clinical phenotype of affected patients, thus suggesting that the detailed mechanisms of transcriptional regulation still remain unclear.
CONCLUSIONS: We describe a novel NKX2-1 mutation and demonstrate that haploinsufficiency may not be the only explanation for BTLS. Our results indicate that NKX2-1 activity is also finely regulated in a tissue-specific manner, and additional studies are required to better understand the complexities of genotype-phenotype correlations in the NKX2-1 deficiency syndrome.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 12914769
Created: 2017-07-12
Species: All species
Last Modified: 2017-07-12
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.